Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity

Oxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological dose-limiting toxicity of OXA-based chemotherapy and includes acute transient neurotoxic effects that appear soon after OX...

Descripción completa

Detalles Bibliográficos
Autores: Velasco, Roser|||0000-0003-3194-9406, Alemany, Montserrat|||0000-0002-7039-4186, Villagrán, Macarena|||0000-0001-9236-2428, Argyriou, Andreas A.|||0000-0003-2131-7114
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:270893
Acceso en línea:https://ddd.uab.cat/record/270893
https://dx.doi.org/urn:doi:10.3390/jpm11070669
Access Level:acceso abierto
Palabra clave:Neurotoxicity
Oxaliplatin
Chemotherapy-induced peripheral neuropathy
Biomarker
Genomics
Neuropathy
FOLFOX
FOLFIRINOX
XELOX
Gastrointestinal cancer
id ES_88a6f3bf424a2ff25812e9cae4f6b1f8
oai_identifier_str oai:ddd.uab.cat:270893
network_acronym_str ES
network_name_str España
repository_id_str
spelling Predictive Biomarkers of Oxaliplatin-Induced Peripheral NeurotoxicityVelasco, Roser|||0000-0003-3194-9406Alemany, Montserrat|||0000-0002-7039-4186Villagrán, Macarena|||0000-0001-9236-2428Argyriou, Andreas A.|||0000-0003-2131-7114NeurotoxicityOxaliplatinChemotherapy-induced peripheral neuropathyBiomarkerGenomicsNeuropathyFOLFOXFOLFIRINOXXELOXGastrointestinal cancerOxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological dose-limiting toxicity of OXA-based chemotherapy and includes acute transient neurotoxic effects that appear soon after OXA infusion, and chronic non-length dependent sensory neuronopathy symmetrically affecting both upper and lower limbs in a stocking-and-glove distribution. No effective strategy has been established to reverse or treat OXAIPN. Thus, it is necessary to early predict the occurrence of OXAIPN during treatment and possibly modify the OXA-based regimen in patients at high risk as an early diagnosis and intervention may slow down neuropathy progression. However, identifying which patients are more likely to develop OXAIPN is clinically challenging. Several objective and measurable early biomarkers for OXAIPN prediction have been described in recent years, becoming useful for informing clinical decisions about treatment. The purpose of this review is to critically review data on currently available or promising predictors of OXAIPN. Neurological monitoring, according to predictive factors for increased risk of OXAIPN, would allow clinicians to personalize treatment, by monitoring at-risk patients more closely and guide clinicians towards better counseling of patients about neurotoxicity effects of OXA. 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/270893https://dx.doi.org/urn:doi:10.3390/jpm11070669reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI20/00283open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2708932026-06-06T12:50:31Z
dc.title.none.fl_str_mv Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
title Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
spellingShingle Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
Velasco, Roser|||0000-0003-3194-9406
Neurotoxicity
Oxaliplatin
Chemotherapy-induced peripheral neuropathy
Biomarker
Genomics
Neuropathy
FOLFOX
FOLFIRINOX
XELOX
Gastrointestinal cancer
title_short Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
title_full Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
title_fullStr Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
title_full_unstemmed Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
title_sort Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
dc.creator.none.fl_str_mv Velasco, Roser|||0000-0003-3194-9406
Alemany, Montserrat|||0000-0002-7039-4186
Villagrán, Macarena|||0000-0001-9236-2428
Argyriou, Andreas A.|||0000-0003-2131-7114
author Velasco, Roser|||0000-0003-3194-9406
author_facet Velasco, Roser|||0000-0003-3194-9406
Alemany, Montserrat|||0000-0002-7039-4186
Villagrán, Macarena|||0000-0001-9236-2428
Argyriou, Andreas A.|||0000-0003-2131-7114
author_role author
author2 Alemany, Montserrat|||0000-0002-7039-4186
Villagrán, Macarena|||0000-0001-9236-2428
Argyriou, Andreas A.|||0000-0003-2131-7114
author2_role author
author
author
dc.subject.none.fl_str_mv Neurotoxicity
Oxaliplatin
Chemotherapy-induced peripheral neuropathy
Biomarker
Genomics
Neuropathy
FOLFOX
FOLFIRINOX
XELOX
Gastrointestinal cancer
topic Neurotoxicity
Oxaliplatin
Chemotherapy-induced peripheral neuropathy
Biomarker
Genomics
Neuropathy
FOLFOX
FOLFIRINOX
XELOX
Gastrointestinal cancer
description Oxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological dose-limiting toxicity of OXA-based chemotherapy and includes acute transient neurotoxic effects that appear soon after OXA infusion, and chronic non-length dependent sensory neuronopathy symmetrically affecting both upper and lower limbs in a stocking-and-glove distribution. No effective strategy has been established to reverse or treat OXAIPN. Thus, it is necessary to early predict the occurrence of OXAIPN during treatment and possibly modify the OXA-based regimen in patients at high risk as an early diagnosis and intervention may slow down neuropathy progression. However, identifying which patients are more likely to develop OXAIPN is clinically challenging. Several objective and measurable early biomarkers for OXAIPN prediction have been described in recent years, becoming useful for informing clinical decisions about treatment. The purpose of this review is to critically review data on currently available or promising predictors of OXAIPN. Neurological monitoring, according to predictive factors for increased risk of OXAIPN, would allow clinicians to personalize treatment, by monitoring at-risk patients more closely and guide clinicians towards better counseling of patients about neurotoxicity effects of OXA.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/270893
https://dx.doi.org/urn:doi:10.3390/jpm11070669
url https://ddd.uab.cat/record/270893
https://dx.doi.org/urn:doi:10.3390/jpm11070669
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI20/00283
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412567973101568
score 15,300724

Similares en LA Referencia